Compare F5 Inc (FFIV) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs DENTSPLY SIRONA Inc — how do they compare? F5 Inc trades at $402.59 (market cap $23.79B), while DENTSPLY SIRONA Inc trades at $13.84 (market cap $2.68B). The key difference: F5 Inc is far larger — about 8.9× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| FFIV | XRAY | |
|---|---|---|
Market Cap | $23.79B | $2.68B |
Sector | Technology | Health |
52-Week High | $431.26 | $16.85 |
52-Week Low | $223.99 | $9.64 |
Enterprise Value | $22.60B | $4.83B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $403.30, down 6.48% on the day, yet maintains a bullish technical trend with strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.90 surpassing the $3.46 expectation. Revenue growth is steady, reaching $3.09 billion in 2025, supported by strategic expansions into AI security, including the acquisition of SurePath AI and new platform launches.
The outlook is positive, driven by robust profitability and strategic positioning in application security. However, risks include high valuation multiples and competitive pressures. Analyst consensus is a 'Hold' with a $397 price target, slightly below the current price, indicating cautious optimism amid growth initiatives.
XRAY trades at $13.76, up 8.35% in 24 hours, with technical indicators showing a bullish trend. The stock has missed earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.36. Revenue declined to $3.68 billion in 2025, and the company reported a net loss of $598 million. Recent news highlights include distribution expansions and new AI-enabled product launches, while analyst sentiment remains mixed with a consensus price target of $13.33.
The outlook for XRAY is cautious due to persistent earnings misses and negative profitability, though technical momentum and strategic initiatives offer some upside potential. Key risks include margin pressure, high debt levels, and soft European demand. Investors should weigh the bullish technical signals against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
